Tumor Suppressors/Apoptosis
Cell Cycle Proteins
Transcription Regulators
Homeodomain Proteins
Steroid Receptors

Kinases and Phosphatases
Growth Factors and Hormones
Membrane Receptors
Signaling Intermediates
GDP/GTP Binding Proteins

Neurobiology
Channel Proteins
Lymphocyte Signaling
Cell Adhesion Proteins
Structural Proteins

siRNA GENE SILENCERS AND IMMUNODETECTION REAGENTS

HEADQUARTERS
Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, California  95060
Tel. 831.457.3800
Toll Free: 800.457.3801

EUROPEAN SUPPORT OFFICE
Santa Cruz Biotechnology, Inc.
Bergheimer Str. 89-2
69115  Heidelberg, Germany
Tel. +49 6221 4503 0
Toll Free: +00800 4573 8000
The National Institute of Allergy and Infectious Diseases (NIAID), the second largest institute of the world-renowned National Institutes of Health (NIH), supports and conducts basic, applied and clinical research to better understand, treat, and prevent infectious, immunologic, and allergic diseases. The Division of Microbiology and Infectious Diseases (DMID) is an extramural research Division of NIAID. The Division supports extramural research related to the control and prevention of diseases caused by virtually all human infectious agents (over 250 pathogens) except HIV. DMID is seeking applications from exceptional candidates for the following position:

**Deputy Director, DMID**

As an extramural research Division, DMID supports a wide variety of projects involving various human pathogens and ranging from basic to clinical research, through the development and evaluation of new drugs, vaccines, and diagnostics. DMID-supported research involves many scientific areas including bacteriology and mycology, biodefense, emerging infectious diseases, enteric diseases, microbial genomics, parasitology, respiratory diseases, sexually transmitted infections, vaccine development, and virology. The Division also participates in global partnerships and maintains a drug development program.

The selected candidate serves as Deputy to the DMID Director and fully shares responsibility for managing DMID’s national / international extramural research program. In collaboration with the Director, the Deputy fully participates in both the planning, administration, development, and evaluation of DMID’s research programs, and in directing, overseeing, and evaluating DMID’s on-going activities through subordinate supervisors, projects leaders, program specialists, and contractor employees. The Deputy represents the Division and the Institute at national and international meetings and conferences; makes scientific/clinical presentations at scientific/medical meetings; and serves as a key scientific advisor to DMID Branch Chiefs, Office Directors and NIAID. The chosen candidate has the ability to encourage participation and partnering with public and private/commercial entities to transition basic research knowledge into the development of products that will improve human health in the U.S. and globally.

Applicants must possess an M.D., Ph.D., or equivalent degree, be a U.S. Citizen, and exhibit a broad scientific vision; an ability to lead a staff; and a demonstrated expertise in managing a broad and complex biomedical research program. The chosen candidate will posses the interpersonal and communication skills required to interact effectively with representatives of academia, private industry, national and international research and health organizations, the media, and the general public.

This vacancy is being advertised under the Title 5 and Title 42 hiring authorities. Salary is commensurate with experience and a full package of benefits is available including retirement, health and life insurance, long term care insurance, leave and savings plan (401K equivalent).


For the Title 42 vacancy, Non-citizens may apply. Please send your curriculum vitae and bibliography to: Pamela McInnes, DDS, MSc(Dent), Director Center for Integrative Biology and Infectious Diseases (CIBID), NIDCR/NIH, Building 45/4AN12B, Bethesda, MD 20892. Direct inquiries to: Dr. Pamela McInnes via email: pmcinnes@nidcr.nih.gov or at 301-443-8618.

The deadline for receipt of all applications is **January 26, 2007**.

We invite you to explore our Institute and view other available opportunities at: [http://healthresearch.niaid.nih.gov/ddjoi](http://healthresearch.niaid.nih.gov/ddjoi)

DHHS and NIH are Proud to be Equal Opportunity Employers
A New Adjuvant from Avanti®

The combination of dimethyl dioctadecyl ammonium bromide and the synthetic cord factor trehalose dibehenate promotes strong protective immune responses, without overt toxicity, against M. tuberculosis infection in a vaccination model and thus appears to be a very promising candidate for the development of human vaccines.*

Made with Avanti’s signature >99% purity. Also available produced under cGMP guidelines.


Phone 800-227-0651 (205-663-2494 International) or Email info@avantilipids.com for details of Avanti’s selection of lipids of unparalleled purity visit www.avantilipids.com

MIDWINTER CONFERENCE OF IMMUNOLOGISTS

www.midwconfimmunol.org

The 2007 Midwinter Conference of Immunologists at Asilomar
January 27-30, 2007
Asilomar Conference Grounds, Pacific Grove, California

Chairpersons: Nilabh Shastri and Steven F. Ziegler

Saturday, January 27
THE DAN H. CAMPBELL MEMORIAL LECTURE - Laurie H. Glimcher

Sunday, January 28
SESSION I: TRANSCRIPTIONAL CONTROL OF IMMUNITY
Speakers: Sankar Ghosh, Dan R. Littman, Stephen T. Smale, Jenny P.-Y. Ting

SESSION II: CHALLENGES REAL AND IMAGINED: INFLAMMATORY RESPONSES IN INFECTION AND ALLERGY
Speakers: Richard M. Locksley, Andrew D. Luster, Anne O’Garra, Steven F. Ziegler

Monday, January 29
SESSION III: INSIDE-OUT SIGNALING: OLD AND NEW PATHWAYS FOR GENERATING TCR LIGANDS
Speakers: Sebastian Amigorena, Peter Cresswell, Mitchell Kronenberg, Nilabh Shastri

SESSION IV: DETERMINING CELL FATE IN THE IMMUNE SYSTEM
Speakers: Douglas R. Green, Kristin A. Hogquist, Warren S. Pear, Susan L. Swain

Tuesday, January 30
SESSION V: AUTOIMMUNITY: WHY AND WHEN THE IMMUNE SYSTEM TURNS AGAINST US
Speakers: Jeffrey A. Bluestone, Diane J. Mathis, Maria-Grazia Roncarolo, Matthias von Herrath

For full program, registration, and additional information, please visit www.midwconfimmunol.org
Accelerating T Regulatory Research

Differentiation of Full-Length vs. FOXP3 Δ2

<table>
<thead>
<tr>
<th>Human FOXP3</th>
<th>Mouse FOXP3</th>
<th>Monoclonal Antibodies to FOXP3 Isoforms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human PBMCs stained with CD4 FITC and FOXP3 (Clone 206D) PE</td>
<td>C57B/6 splenocytes stained with FOXP3 (clone 150D) Alexa Fluor647</td>
<td>WB analysis of cell lysate from Human PBMCs, using anti-FOXP3 mAbs 2590, 206D, and 150D</td>
</tr>
<tr>
<td>Applications: Flow Cytometry, IHC, WB</td>
<td>Applications: Flow Cytometry, IHC, WB</td>
<td>Applications: Flow Cytometry, IHC, WB</td>
</tr>
</tbody>
</table>

FOXP3 is a hallmark of Treg cells. Two isoforms of FOXP3, full length FOXP3 and FOXP3Δ2 (which lacks exon 2), have been found in humans. Clones 259D and 206D recognize both full-length FOXP3 (upper band) and the FOXP3Δ2 splice variant (lower band), while clone 150D recognizes only full-length FOXP3, indicating that this antibody recognizes an epitope in the exon 2 region.

BioLegend
The path to legendary discovery
World-Class Quality, Superior Customer Support, Outstanding Value.